Mechanisms involved in the side effects of glucocorticoids
The DOI matches its Crossref record; 211 of the 211 references it cites were found in a registry or an index.
Abstract
Glucocorticoids (GCs) represent the most important and frequently used class of anti-inflammatory drugs. While the therapeutic effects of GCs have been known and used for more than 50 years, major progress in discovering the underlying molecular mechanisms has only been made in the last 10-15 years. There is consensus that the desired anti-inflammatory effects of GCs are mainly mediated via repression of gene transcription. In contrast, the underlying molecular mechanisms for GC-mediated side effects are complex, distinct, and frequently only partly understood. Recent data suggest that certain side effects are predominantly mediated via transactivation (e.g., diabetes, glaucoma), whereas others are predominantly mediated via transrepression (e.g., suppression of the hypothalamic-pituitary-adrenal axis). For a considerable number of side effects, the precise molecular mode is either so far unknown or both transactivation and transrepression seem to be involved (e.g., osteoporosis). The differential molecular regulation of the major anti-inflammatory actions of GCs and their side effects is the basis for the current drug-finding programs aimed at the development of dissociated GC receptor (GR) ligands. These ligands preferentially induce transrepression by the GR, but only reduced or no transactivation. This review summarizes the current knowledge of the most important GC-mediated side effects from a clinical to a molecular perspective. The focus on the molecular aspects should be helpful in predicting the potential advantages of selective GR agonists in comparison to classical GCs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Serious adverse events are in general more likely to occur in systemic corticosteroid users and especially with longer duration and higher dosage of use (30).”
From Approach to the Patient: Diagnosis of Cushing Syndrome (2022) · cites this paper as [30]
In the citing paper
“their therapeutic actions are counterbalanced by adverse side effects associated with high doses and long-term use, such as osteoporosis, skin atrophy, diabetes, hypertension, abdominal obesity, acne, infection, and growth retardation [8], as well as ocular hypertension [9].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [8]
In the citing paper
“These side effects include osteoporosis, skin atrophy, diabetes, abdominal obesity, glaucoma, cataracts, avascular necrosis and infection, growth retardation, and hypertension3.”
From Corticosteroids (2016) · cites this paper as [3]
In the citing paper
“Long-term topical and systemic use of glucocorticoids is associated with skin atrophy, disruption to cutaneous barrier function, and dermatitis [86].”
From Boosting the Photoaged Skin: The Potential Role of Dietary Components (2021) · cites this paper as [86]
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Primary structure and expression of a functional human glucocorticoid receptor cDNA
Hollenberg, S. M., Weinberger, C., Ong, E. S., Cerelli, G., Oro, A., Lebo, R., Brad Thompson, E., Rosenfeld, M. G., & Evans, R. M. (1985) · Nature · doi:10.1038/318635a0 · Cited by 1,869
Dennler, S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3091 · Cited by 1,793
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753
Molecular Mechanisms of Human Hypertension
Lifton, R. P., Gharavi, A. G., & Geller, D. S. (2001) · Cell · doi:10.1016/s0092-8674(01)00241-0 · Cited by 1,686
Anti-inflammatory Actions of Glucocorticoids: Molecular Mechanisms
Barnes, P. J. (1998) · Clinical Science · doi:10.1042/cs0940557 · Cited by 1,591
The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum.
(1975) · PubMed Central · Cited by 1,437
Gould, E., Tanapat, P., McEwen, B. S., Flügge, G., & Fuchs, E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3168 · Cited by 1,395
Cited by
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Bel, E. H., Wenzel, S. E., Thompson, P. J., Prazma, C. M., Keene, O. N., Yancey, S. W., Ortega, H. G., & Pavord, I. D. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403291 · Cited by 1,661
American Society of Hematology 2019 guidelines for immune thrombocytopenia
Neunert, C., Terrell, D. R., Arnold, D. M., Buchanan, G., Cines, D. B., Cooper, N., Cuker, A., Despotovic, J. M., George, J. N., Grace, R. F., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000966 · Cited by 1,406
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease
Ruemmele, F. M., Veres, G., Kolho, K. L., Griffiths, A., Levine, A., Escher, J. C., Amil Dias, J., Barabino, A., Braegger, C. P., Bronsky, J., et al. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.04.005 · Cited by 1,083
Metadata
- Authors
- SCHACKE, H.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2002-10
- Volume
- 96
- Issue
- 1
- Pages
- 23-43
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W1997103341
- Cited by
- 1,847
- References
- 209
- Citations by year
- 2026: 40 · 2025: 78 · 2024: 94 · 2023: 87 · 2022: 80 · 2021: 95 · 2020: 120 · 2019: 98 · 2018: 94 · 2017: 90 · 2016: 118 · 2015: 97 · 2014: 102 · 2013: 88 · 2012: 116
- FWCI
- 12.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- glucocorticoids, glucocorticoid adverse effects, glucocorticoid receptor, transcriptional activation, transrepression, transcriptional repression, anti-inflammatory mechanism, selective glucocorticoid receptor agonists, diabetes mellitus, glaucoma, hypothalamic-pituitary-adrenal axis, osteoporosis
- MeSH terms
- Animals, Anti-Inflammatory Agents, Atrophy, Mental Disorders, Diabetes Mellitus, Glaucoma, Glucocorticoids, Growth Disorders, Humans, Hypertension, Hypothalamo-Hypophyseal System, Immune System, Organ Specificity, Osteoporosis, Pituitary-Adrenal System, Receptors, Glucocorticoid, Skin, Steroids, Wound Healing, Muscle, Skeletal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms involved in the side effects of glucocorticoids. https://app.cochat.ai/papers/10.1016/s0163-7258(02)00297-8
- The paper
- SCHACKE, H. (2002). Mechanisms involved in the side effects of glucocorticoids. Pharmacology & Therapeutics. https://doi.org/10.1016/s0163-7258(02)00297-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.